Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1

Interventions

Cyclophosphamide 17Cytarabine 11venetoclax 9fludarabine 9Mycophenolic Acid 8Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6ruxolitinib 5Tacrolimus 5Methotrexate 5Daunorubicin 5Cyclosporine 5Azacitidine 5ponatinib 4Vincristine 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Dexamethasone 4blinatumomab 3asciminib 3Prednisone 3Mercaptopurine 3Inotuzumab Ozogamicin 3Doxorubicin 3revumenib 2quizartinib 2pegfilgrastim 2pegaspargase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × pegylated granulocyte colony-stimulating factor, human × 90 days × Clear all
NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡